{"id":"NCT02955212","sponsor":"AbbVie","briefTitle":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-03","primaryCompletion":"2019-08-14","completion":"2020-09-03","firstPosted":"2016-11-04","resultsPosted":"2020-08-06","lastUpdate":"2021-09-27"},"enrollment":338,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis (RA)"],"interventions":[{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo / Upadacitinib 15 mg","type":"PLACEBO_COMPARATOR"},{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL"}],"summary":"The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including Brazil and South Korea with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs.\n\nThe study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in subjects with RA who have completed Period 1.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":31.4,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":71.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":43,"countries":["Brazil","China","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":169},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","ALANINE AMINOTRANSFERASE INCREASED","BLOOD CREATINE PHOSPHOKINASE INCREASED","HEPATIC FUNCTION ABNORMAL","ANAEMIA"]}}